Special Issue "Novel Biosensing Platforms for Disease Diagnosis: Translation of Lab-based Technologies into Clinical Settings"
A special issue of Biosensors (ISSN 2079-6374).
Deadline for manuscript submissions: closed (31 May 2018)
Dr. Fatih Inci
Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, 3155 Porter Drive, Palo Alto, CA 94304, USA
Website | E-Mail
Interests: microfluidics; lab-on-a-chip; plasmonic biosensors; bionanotechnology; nanoplasmonics; wearable sensors; infectious diseases; HIV/AIDS; cancer research; personalized medicine; point of care diagnostics; mobile health; global health; biomedical engineering; molecular diagnostics; telemedicine
The field of biosensing has seen unprecedented growth in the last decade, and recent advances in this field have revolutionized today’s clinical practice by providing innovative solutions to research laboratories and clinical settings. Particularly, biosensing technologies have created unique bridges between sensors technologies and biological needs, as well as drawn up contributions from chemistry, physics, materials science, and engineering. Integration of innovative biosensing technologies at the intersection of nano- and micro-scale denotes remarkable opportunities for addressing critical challenges in biology and medicine, and also presents a wide range of applications in clinics such as diagnosis, therapy monitoring, single cell detection, downstream genomic analysis and combating various maladies.
Biosensing approaches constitute multiple parameters, including (i) chip and sensor design, (ii) specialized surface chemistry, (iii) biological target and specimen, and (iv) clinical validation. These parameters are also evaluated with sensing performance and capabilities such as limit of detection, specificity, background noise, and linear dynamic range. Prior to their translation, aforementioned points, especially clinical validations, are uniquely addressed.
In this Special Issue, we will focus on innovative biosensing technologies, including plasmonics, nanoplasmonics, electrochemical sensing, wearable technologies, paper-based detection strategies, and mechanical modalities. Moreover, we seek the significance of unique materials and sensor components (smart polymers, metamaterials, aptamers, imprinted surfaces, click-chemistry approaches, synthetic antibodies, and so on), as well as review novel biomarkers, e.g., circulating DNAs, exosomes, volatile organic compounds, from multiple biosepecimen types, including tears, saliva, serum, urine, and breath.
Dr. Fatih Inci
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 650 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.